Health care stocks were advancing premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.
Novartis (NVS) will keep manufacturing treatments for malaria and leprosy even if regular orders stop due to global health funding cuts, Reuters reported, citing its global health president. The company's shares were down more than 2% pre-bell.
ImmunityBio (IBRX) stock was up more than 4% after the company reported a narrower Q1 net loss as revenue increased during the period.
Dr. Reddy's Laboratories (RDY) shares were up past 3% after the company posted higher fiscal Q4 earnings and revenue.